{"name":"Lexicon Pharmaceuticals","slug":"lexicon","ticker":"LXRX","exchange":"NASDAQ","domain":"lexpharma.com","description":"Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.","hq":"The Woodlands, TX","founded":0,"employees":"81","ceo":"Lonnel Coats","sector":"Cardiometabolic","stockPrice":2.37,"stockChange":-0.07,"stockChangePercent":-2.87,"marketCap":"$1.1B","metrics":{"revenue":49803000,"revenueGrowth":-79.3,"grossMargin":86.8,"rdSpend":61121000,"netIncome":-50341000,"cash":96230000,"dividendYield":0,"peRatio":-11.5,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2038-06-01","label":"Zynquista patent cliff ($1.4B at risk)","drug":"Zynquista","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Schedule B","genericName":"Schedule B","slug":"schedule-b","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Schedule B","genericName":"Schedule B","slug":"schedule-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"Lexicon Pharmaceuticals Announces FDA Approval of Zynquista (sotagliflozin) for the Treatment of Type 1 Diabetes","summary":"The FDA has approved Zynquista (sotagliflozin) for the treatment of type 1 diabetes.","drugName":"Zynquista","sentiment":"positive"},{"date":"2022-02-24","type":"earnings","headline":"Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results","summary":"Lexicon Pharmaceuticals reported its fourth quarter and full year 2021 financial results, with revenue of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2021-05-28","type":"deal","headline":"Lexicon Pharmaceuticals Announces Collaboration with Sanofi to Develop and Commercialize Sotagliflozin for Type 2 Diabetes","summary":"Lexicon Pharmaceuticals has entered into a collaboration with Sanofi to develop and commercialize sotagliflozin for type 2 diabetes.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPbmNRUXZmdjlpZGtkWGNYZ2Q2UUNoTlkxUGNMV2x5Wm55M2F5c3JTa3ZUMWRlQUMwT1FZQ1REOWZKYzFWRUVQUjNfSnl4c1Z3Z3lHR05jMzY2OXRUNTB5UXQ2MGdVN0lyaWlQbDZZYW1rN3ptUnI3TXdTSzJ4WURWNWszcy1NbzEtdU1qbjA4d2pLZWNndk5HUWptN1dhb2hvZmtrTHhJZjdWZDJJM2NScDQxOXJUY3F0dVV3?oc=5","date":"2026-03-11","type":"pipeline","source":"Stock Titan","summary":"Diabetes drug sotagliflozin cut low-sugar events, across kidney stages - Stock Titan","headline":"Diabetes drug sotagliflozin cut low-sugar events, across kidney stages","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPTkgzZ052dmFGMUdHbFVoa21RVmpaakxLakE4SWlQUFRnaXFJaFl5QXVJc3VyZlN3VDl5U1o2T0NvNXZSRENsenllME5DVGg4ZER5UllmeUdvOVdUS3cyaTR3SWJ2VE1ockRqWkhOaWxPeHJyQ2RiUlFnZy1oRkdnc2pzaFJVSUwwblFKU05NTF9RQTN6WkN1eG5VMG5CTmNaUkpqZWp6MnFVUTRVZjVBYjNNUExEWDA?oc=5","date":"2026-03-05","type":"trial","source":"Stock Titan","summary":"Lexicon wins Phase 3 go-ahead for pain drug and $100M cash boost - Stock Titan","headline":"Lexicon wins Phase 3 go-ahead for pain drug and $100M cash boost","sentiment":"neutral"},{"date":"2026-03-05","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQT3lpLWhlVEN4RUkxOVBVekQxM1k4RUkzbzczaEZMZm44VjZ5VGhkbEE2Y2p0b3BaZ3UxOV9tdzIxTEdQQUt1LUNMRjVNR1BFRUtjOXM4azZaN29qSGlNNDZWQzEtR1lzNmxfSmlaWDM5MnNySUxoT0ZRM2gwRFRtNlVEd20tdDJuVDVSdDVzbUdGcklGV0ROWDE0d0diQ1ZIQjN3cEM1c3poLXBpZkRabUszRHdma3lC?oc=5","date":"2026-03-03","type":"pipeline","source":"Stock Titan","summary":"Lexicon Pharma plans Miami fireside chat, 3 investor events in March - Stock Titan","headline":"Lexicon Pharma plans Miami fireside chat, 3 investor events in March","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxObjlZTDQyOTJBWFZmem5EMTRPc0p5NnkzVXZKc28xOEM3RE5aQ0RnZk9mSC1KYWpQaC1Zc3RZRmtpM0pEWUhoT1RxV2FjaFh5c2NsYW1SSUU4MzFJWVY2TWJtZy1LMi0tUGo5eXY5cXNjcHhlRXVFSkRGMlJmWmJvWGk3TQ?oc=5","date":"2026-02-19","type":"deal","source":"Seeking Alpha","summary":"Lexicon Pharma spikes after insider buy - Seeking Alpha","headline":"Lexicon Pharma spikes after insider buy","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st","headline":"Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNNms5cmU1a0FMblVWXzBla01Bb3M5QmpXUjZiQUJQLUFCMnM2bWxvbXYwSHNMLTVvenFRTkNOak9QbVJEZE1LdzJhLUVJNUpIUldIMGY2OXZwMWt1dGdSbEg1Qk1tWHhsRE5KbThyZXJiUWJfeEFOam1JREE1Z21nanR2SFk?oc=5","date":"2026-01-21","type":"regulatory","source":"Seeking Alpha","summary":"Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ) - Seeking Alpha","headline":"Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQNHBnaVFFNE1DSzYwWWlMcWlwZDdmRjNwWUpfOXZCeWJSTGc5aHZROWo4UmpmOEh5c0d5QUpFVnpRczhwWUpRMzZxM3J5WG5HQUtFaUYyVnIzWlZBN19heWwzbmpsY29xR3BtRElXSnNDRnY3RmhIMkNERk5Sa1VZd1ZWU09maHNQS1o2Mjl4MW1MRnlpNWZseU53cEhqTUJFX3p3?oc=5","date":"2025-11-15","type":"pipeline","source":"Seeking Alpha","summary":"Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win (NASDAQ:LXRX) - Seeking Alpha","headline":"Lexicon Pharmaceuticals: A Lottery Ticket With 3 Chances To Win (NASDAQ:LXRX)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"pipeline","source":"simplywall.st","summary":"Private equity firms among Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders, saw gain in holdings value after stock jumped 17% last week - simplywall.st","headline":"Private equity firms among Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders, saw gain in holdings valu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOTXFxSGR4eFF0M1ZNczU5Y29mWDJzVmtVNzNaNnpSbUJsZVB6UHNQdnR1bzZWTS11S2M5bENxRjh2WlQ1YS0zWmc2WTF6SnBVYjlOTGZDX0dNODFOeG0wcmVvamxBSHFqMVNEbEREQWE0NEVLTkUycHB2TzJkQUY4VjBpM191bkJFR1RzZ3NvMXVMVXFXT05mMw?oc=5","date":"2025-03-28","type":"pipeline","source":"MedCity News","summary":"Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s - MedCity News","headline":"Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNZHk1cXVmNkpHQS1uMkowaFFtRExSeHg1U09DQUc5RTg4QkhxMmVIZVhpZmdEaUE0UzNWWmEtU3ZlQzdRZ3REYVFYOVZnTHBqc0VUNmJHRWtlTFE4M2xSeWIwUDVNNlRKUGN3UF9JdHRlRW5yZUlodWhid0daLU94dGhCUWtkalA1U2xYSHN2UVduU1R2dUtxUE1kYWdWS293YkNicG1sbFNwSkxYLUNCRHd3?oc=5","date":"2025-01-07","type":"pipeline","source":"Investing.com","summary":"Lexicon Pharmaceuticals faces potential Nasdaq delisting - Investing.com","headline":"Lexicon Pharmaceuticals faces potential Nasdaq delisting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQRThmcS0wNVdsbUtSX1NKYkdFWHdveXVpWUsxbFBjUEZVQVE0cHFFZTZ3RUN1SmxRZUR1bm5zSms2Rm5VOWVuWU9WTmFEYzd3bHBwLXpLR0d4NFZWTnlubnVUZ2N2T211eHJyRU1wQ3phclNXamJDVmRyeVIxZkxqRl84RjlrM3ZDaldfQ3FKam5GWUdGWWhLS3M4TkN4bmZFNENvYmQ2VnREaUF0bWNxMjI1c2wybmpYeXQ2OVhqMGU0TGUtUE1OdnZVOUU4LUczVTRrdjBYajg?oc=5","date":"2024-10-31","type":"regulatory","source":"Reuters","summary":"FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters","headline":"FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE80ZGpSQlROSWZWLWNSLXV5ekxUeFhkY1FNRWtUX19WTUhQa19xbXgtYUhuLUZwMmxydEFkX3lDdVlZTlJvb1BGSS1IN01meWpx?oc=5","date":"2024-01-11","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Zynquista","drugSlug":"sotagliflozin","patentNumber":"","type":"Patent Cliff","expiryDate":"2038-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["AstraZeneca","Merck & Co.","Novo Nordisk"],"therapeuticFocus":["Diabetes","Cardiovascular Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":49803000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":49803000,"period":"2025-12-31"},{"value":31081000,"period":"2024-12-31"},{"value":31081000,"period":"2024-12-31"},{"value":1204000,"period":"2023-12-31"},{"value":1204000,"period":"2023-12-31"}],"grossProfit":49529000,"grossProfitHistory":[{"period":"2025-12-31","value":49529000},{"period":"2024-12-31","value":30465000},{"period":"2023-12-31","value":1119000},{"period":"2022-12-31","value":139000}],"rdSpend":61121000,"rdSpendHistory":[{"period":"2025-12-31","value":61121000},{"period":"2024-12-31","value":84480000},{"period":"2023-12-31","value":58887000},{"period":"2022-12-31","value":52816000}],"sgaSpend":37319000,"operatingIncome":-48911000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-48911000},{"period":"2024-12-31","value":-197117000},{"period":"2023-12-31","value":-171750000},{"period":"2022-12-31","value":-100760000}],"netIncome":-50341000,"netIncomeHistory":[{"period":"2025-12-31","value":-50341000},{"period":"2024-12-31","value":-200403000},{"period":"2023-12-31","value":-177119000},{"period":"2022-12-31","value":-101944000}],"eps":-0.63,"epsHistory":[{"period":"2024-12-31","value":-0.63},{"period":"2023-12-31","value":-0.79},{"period":"2022-12-31","value":-0.62},{"period":"2021-12-31","value":-0.6}],"cash":34326000,"cashHistory":[{"period":"2025-12-31","value":34326000},{"period":"2024-12-31","value":66656000},{"period":"2023-12-31","value":22465000},{"period":"2022-12-31","value":46345000}],"totalAssets":184987000,"totalLiabilities":77449000,"totalDebt":62819000,"equity":107538000,"operatingCashflow":-67851000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-67851000},{"period":"2024-12-31","value":-178780000},{"period":"2023-12-31","value":-161897000},{"period":"2022-12-31","value":-88851000}],"capex":-1031000,"capexHistory":[{"period":"2024-12-31","value":-1031000},{"period":"2023-12-31","value":-470000},{"period":"2022-12-31","value":-1326000},{"period":"2021-12-31","value":-1221000}],"freeCashflow":-67851000,"dividendsPaid":null,"buybacks":-572000,"employees":81,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":8757000,"ebit":-13499000,"ebitda":-13381000,"period":"2025-12-31","revenue":5493000,"epsBasic":-0.04,"netIncome":-15530000,"rdExpense":11315000,"epsDiluted":-0.04,"grossProfit":5292000,"operatingIncome":-14780000},{"sga":7602000,"ebit":-10614000,"ebitda":-10463000,"period":"2025-09-30","revenue":14182000,"epsBasic":-0.04,"netIncome":-12769000,"rdExpense":18757000,"epsDiluted":-0.04,"grossProfit":14172000,"operatingIncome":-12187000},{"sga":9350000,"ebit":5570000,"ebitda":5746000,"period":"2025-06-30","revenue":28866000,"epsBasic":0.01,"netIncome":3252000,"rdExpense":15747000,"epsDiluted":0.01,"grossProfit":28833000,"operatingIncome":3736000},{"sga":11608000,"ebit":-23460000,"ebitda":-23284000,"period":"2025-03-31","revenue":1262000,"epsBasic":-0.07,"netIncome":-25295000,"rdExpense":15303000,"epsDiluted":-0.07,"grossProfit":1232000,"operatingIncome":-25679000},{"sga":32258000,"ebit":-29908000,"ebitda":-29783000,"period":"2024-12-31","revenue":26554000,"epsBasic":-0.09,"netIncome":-33766000,"rdExpense":26685000,"epsDiluted":-0.09,"grossProfit":26206000,"operatingIncome":-32737000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.37,"previousClose":2.44,"fiftyTwoWeekHigh":2.53,"fiftyTwoWeekLow":0.51,"fiftyTwoWeekRange":"0.51 - 2.53","fiftyDayAverage":1.72,"twoHundredDayAverage":1.41,"beta":0.97,"enterpriseValue":677790400,"forwardPE":-11.5,"priceToBook":7.99,"priceToSales":21.09,"enterpriseToRevenue":13.61,"enterpriseToEbitda":-14.04,"pegRatio":0,"ebitda":-48290000,"ebitdaMargin":-97,"freeCashflow":-47815248,"operatingCashflow":-67851000,"totalDebt":62237000,"debtToEquity":57.9,"currentRatio":4.88,"returnOnAssets":-12.6,"returnOnEquity":-39.7,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":3.72,"targetHighPrice":6,"targetLowPrice":1.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1,"institutionHeldPercent":65.2,"sharesOutstanding":444196390,"floatShares":417795687,"sharesShort":23674019,"shortRatio":10.17,"shortPercentOfFloat":5.6,"epsTrailing":-0.07,"epsForward":-0.21,"revenuePerShare":0.14,"bookValue":0.3,"officers":[{"age":55,"name":"Dr. Michael S. Exton Ph.D.","title":"CEO & Director"},{"age":58,"name":"Mr. Scott M. Coiante","title":"Senior VP & CFO"},{"age":52,"name":"Mr. Brian T. Crum","title":"Senior VP, General Counsel & Secretary"},{"age":54,"name":"Ms. Wendy E. McDermott","title":"Senior Vice President of Human Resources"},{"age":60,"name":"Dr. Craig B. Granowitz M.D., Ph.D.","title":"Senior VP & Chief Medical Officer"},{"age":57,"name":"Ms. Kristen L. Alexander","title":"Vice President of Finance & Accounting"},{"age":45,"name":"Ms. Lisa M. DeFrancesco","title":"Senior Vice President of Investor Relations & Corporate Communications"},{"age":52,"name":"Dr. Suma  Gopinathan M.S., Ph.D.","title":"Senior Vice President of Discovery"}],"industry":"Biotechnology","irWebsite":"http://www.lexpharma.com/investors/index.html","website":"https://www.lexpharma.com","phone":"281 863 3000"}}